文献速递淋巴瘤

雌激素受体β刺激作为皮肤T细胞淋巴瘤潜在新型治疗靶点

Estrogen receptor β stimulation as a possible novel therapeutic target for cutaneous T-cell lymphoma.
PubMed 文献 · Blood Adv · 2025-01-01

本研究探讨选择性雌激素受体β(ERβ)激动剂LY500307对皮肤T细胞淋巴瘤(CTCL)的治疗潜力。体外实验显示LY500307选择性降低CTCL细胞活力并保留正常皮肤细胞,诱导凋亡、G2/M期阻滞并增加化疗敏感性;CTCL异种移植小鼠模型中LY500307显著减少肿瘤生长且无明显毒性。作者认为LY500307是有前景的CTCL治疗药物,需进一步临床研究包括局部应用的可能性。

要点

  • LY500307选择性降低CTCL细胞活力,不损害正常皮肤细胞。
  • LY500307诱导CTCL细胞凋亡、G2/M期阻滞并增加化疗敏感性。
  • CTCL异种移植小鼠模型中LY500307显著减少肿瘤生长且无明显毒性。

核心结论

  • 作者认为LY500307是皮肤T细胞淋巴瘤有前景的治疗药物,需进一步临床研究,包括局部应用的可能性。

研究设计与样本

  • 本研究为体外细胞实验与CTCL异种移植小鼠模型研究,评估选择性ERβ激动剂LY500307对CTCL的作用。
  • 研究对象为皮肤T细胞淋巴瘤(CTCL),包括蕈样肉芽肿(MF)和Sézary综合征(SS)。

主要发现

  • LY500307选择性降低CTCL细胞活力,保留非癌性皮肤细胞。
  • 液相色谱-串联质谱分析显示CTCL细胞内LY500307蓄积浓度显著高于正常皮肤细胞,可能贡献其选择性细胞毒性。
  • LY500307诱导CTCL细胞凋亡、G2/M期细胞周期阻滞,并增加对化疗药物(尤其是单甲基澳瑞他汀E)的敏感性。
  • CTCL异种移植小鼠模型中LY500307治疗显著减少肿瘤生长,无明显毒性。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文结论指出需进一步临床研究,包括局部应用的可能性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cutaneous T-cell lymphomas (CTCLs), including mycosis fungoides (MF) and Sézary syndrome (SS), are rare hematological malignancies with limited curative treatment options. Despite early-stage responsiveness, these malignancies often relapse in advanced stages, highlighting the need for novel, durable therapies. Similar to other non-Hodgkin lymphomas (NHLs), MF and SS have a greater incidence rate in males than females. The endocrine contribution to this sex difference is unknown. Although several studies could show a potential role of estrogen receptor β (ERβ) on NHL lymphomagenesis, its impact on CTCL development is unknown. In this study, we investigated LY500307, a selective ERβ agonist, as a potential treatment for CTCL. Our results show that LY500307 selectively reduced the viability of CTCL cells, sparing noncancerous skin cells. Liquid chromatography with tandem mass spectrometry analysis revealed that CTCL cells accumulated significantly higher concentrations of LY500307 than normal skin cells, likely contributing to its selective cytotoxicity. Mechanistically, LY500307 induced apoptosis, G2/M cell cycle arrest, and increased sensitivity to chemotherapeutic agents, particularly Monomethyl auristatin E. Furthermore, LY500307 treatment significantly reduced tumor growth in a CTCL xenograft mouse model without notable toxicity. These findings suggest LY500307 as a promising therapeutic agent for CTCL, warranting further clinical investigation, including the potential for topical applications.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Özistanbullu D, Wilhelm R, Reichenbach G, et al. Estrogen receptor β stimulation as a possible novel therapeutic target for cutaneous T-cell lymphoma. Blood Adv. 2025. PMID: 40020159. doi:10.1182/bloodadvances.2024015132

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。